urb597
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2015 (NCT00916201)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Anandamide amidohydrolaseINHIBITOR
FAAH inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester
- urb597
- urb597
- urb597
- urb 597
- urb-597
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00916201 | Phase 1 | Dec 1, 2015 | Max Planck Institute, University of Heidelberg |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Max Planck Institute | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Heidelberg | Academic/Hospital | 1 | 1 | 1 | 2015 |
2 organizations
Page 1 / 1